Advancing the Diagnostic-to-Treatment Continuum in Cancer Care

Phoenix is emerging as a hub for healthcare innovation and precision medicine. In February 2026, we’re bringing two of our most impactful programs—Advancing Pathology Education (APE) and Advancing Precision Oncology (APO)—together in one unified experience that connects state-of-the-art diagnostics with real-world therapeutic decision-making.

The program is co-chaired by Xia Li, PhD, Medical Director of the Molecular Pathology Laboratory at Clin-Path Associates, PLC and Associate Professor of Pathology at the University of Arizona, and Howard McLeod, PharmD, Professor and Center Director at Utah Tech University. Together, they bring complementary perspectives spanning molecular diagnostics, genomics, and precision therapeutics—bridging laboratory innovation with clinical application.

Participants will gain practical, clinically relevant insights into molecular pathology, biomarker interpretation, pharmacogenomics, and therapy optimization through a program designed to foster meaningful collaboration between pathology laboratories, oncology teams, and translational researchers.

What this unified program delivers

• Diagnostic excellence → treatment impact: See how innovations in biomarker testing, AI-driven image analysis, and molecular techniques (NGS, IHC, PCR, liquid biopsy) directly shape care pathways.
• Biomarker deep dives: Practical insights into HER2-low, MET (c-MET), BRAF, Trop-2, FOLR1, FGFR2b, and more—covering analytical pitfalls, reporting, and therapeutic relevance.
• Therapy guided by diagnostics: Explore biomarker-informed strategies across solid tumors and hematologic malignancies, including ctDNA for monitoring, early detection, and response assessment.
• Team-based workflows: Integrate lab and clinic to accelerate decisions and improve outcomes.

Integrated focus areas

Advancing Pathology Education (APE)
Where diagnostic excellence shapes treatment success. Learn how next-generation testing and AI augment accuracy and turnaround, with actionable guidance for biomarker reporting that clinicians can use immediately.

Advancing Precision Oncology (APO)
Turning diagnostic insights into targeted treatments. Examine how molecular findings inform therapy selection, sequencing, and surveillance across tumor types, incorporating ctDNA into modern care algorithms.

Who should attend

• Pathology & Laboratory Medicine: Pathologists, molecular scientists, laboratory directors, translational researchers.
• Clinical Care Teams: Oncologists, hematologists, and multidisciplinary cancer teams (APPs, pharmacists, nurse navigators).

Why Attend?

• FREE registration and CME credits 
• Expert-led presentations, interactive sessions, and case-based discussions designed to translate innovation into practice.
• Practical strategies you can apply immediately in pathology and oncology.
• Engage with a broader network of experts across the diagnostic and therapeutic spectrum
• A chance to connect with clinicians, researchers, and healthcare leaders driving the future of cancer care.

Stay at the forefront of precision oncology—join us in Phoenix for two days of learning, collaboration, and innovation.